 At each study site Birmingham,Cincinnati, Los Angeles, and Providence, the investigators will recruit 300 patients for a total of 1200 patients. Participants will be randomly assigned to receive HIVAIDS and HIV testing information from a comparable pictorial brochure or a video. Randomization will be stratified by health literacy level lower vs. higher and language English or Spanish. Those who are study eligible will undergo verbal consent to conduct the pre- and post-information questionnaires and information delivery portions of the study video or pictorial brochure. No patient identifiers will be collected during the screening process, pre- or post-information questionnaires, or the information delivery phase of the study. For those who agree to be in the next portion of the study, written consent to participate will be obtained. Written consent will be obtained at this juncture because HIV testing and follow-up is performed, and because patient identifiers are needed for the remainder of the study. Participants will complete the study instruments at enrollment and at 3, 6, 9, and 12 months follow-up. At the end of one year, they will be offered the opportunity to be retested for HIV. 